Hepatitis B virus (HBV) remains a leading cause of liver-related morbidity and mortality
through chronic hepatitis that may progress to liver cirrhosis and cancer. The central role …

The liver's unique characteristics have a profound impact on the priming and maintenance of
adaptive immunity. This review delves into the cellular circuits that regulate adaptive …

Objective Hepatitis B virus (HBV)-specific T cells are main effector cells in the control of HBV
infection and hepatitis B surface antigen (HBsAg) is suggested to be a critical factor in the …

Even though an approved vaccine for hepatitis B virus (HBV) is available and widely used,
over 257 million individuals worldwide are living with chronic hepatitis B (CHB) who require …

In diverse viral infections, the production of excess viral particles containing only viral
glycoproteins (subviral particles or SVP) is commonly observed and is a commonly evolved …

Background A functional cure for chronic HBV could be achieved by boosting HBV-specific
immunity. In vitro studies show that immunotherapy could be an effective strategy. However …

Background Cellular immunodeficiency and comorbidities are common in COVID-19
patients. Aim The purpose of this study was to investigate comorbidities impacting on the …

Chronic hepatitis B (CHB) remains a global healthcare burden. Although the recent
developments in the field have led to a reduction in incidence, the morbidity and mortality …

Hepatitis B virus (HBV) and hepatitis delta virus (HDV) are highly prevalent viruses
estimated to infect approximately 300 million people and 12–72 million people worldwide …

Background & Aims RG6346 is an N-acetyl-D-galactosamine (GalNAc)-conjugated, double-
stranded RNA interference agent targeting the HBV genome S-region. We investigated the …